At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune responses and clinical outcomes in STAND, a randomised phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer after local therapy failure.
Immune responses and clinical outcomes in STAND trial of sipuleucel-T and ADT in prostate cancer
23rd July 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now